Singapore, February 14, 2025 – Update on the Detection of the latest SARS-CoV-2 Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing primers and probes of the assays involving SARS-CoV-2 virus detection to all sequences listed in NCBI Virus and GISAID up till February 14th, 2025.
We are pleased to announce that the VitaPCR™ and VitaSIRO solo™ system can detect the concerned SARS-CoV-2 variants and lineages as listed in the table below.
Our analysis has confirmed that the performance of our SARS-Cov-2 detection assays* are not impacted by the variants.
*The SARS-CoV-2 RNA detection assays include:
- VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
- VitaPCR™ SARS-CoV-2 Assay (PCRAE0114)
- VitaPCR™ SARS-CoV-2 Gen 2 Assay (PCRAE0120)
- VitaSIRO solo™ SARS-CoV-2/Flu/RSV Assay (PCRAD1102, PCRAD1112)
For more information, contact us at service@credodxbiomed.com
